NASDAQ:MYOK - Myokardia Stock Price, News & Analysis

$52.64
-0.71 (-1.33 %)
(As of 09/17/2019 11:08 AM ET)
Today's Range
$52.23
Now: $52.6450
$53.7050
50-Day Range
$50.12
MA: $53.58
$56.53
52-Week Range
$39.01
Now: $52.6450
$67.79
Volume55,117 shs
Average Volume188,983 shs
Market Capitalization$2.43 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MYOK
CUSIPN/A
Phone650-741-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.56 million
Book Value$9.20 per share

Profitability

Net Income$-67,700,000.00
Net Margins-201.81%

Miscellaneous

Employees165
Market Cap$2.43 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive MYOK News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOK and its competitors with MarketBeat's FREE daily newsletter.


Myokardia (NASDAQ:MYOK) Frequently Asked Questions

What is Myokardia's stock symbol?

Myokardia trades on the NASDAQ under the ticker symbol "MYOK."

How were Myokardia's earnings last quarter?

Myokardia Inc (NASDAQ:MYOK) issued its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.79) by $0.04. Myokardia had a negative return on equity of 22.02% and a negative net margin of 201.81%. View Myokardia's Earnings History.

When is Myokardia's next earnings date?

Myokardia is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Myokardia.

What price target have analysts set for MYOK?

8 brokers have issued twelve-month target prices for Myokardia's shares. Their forecasts range from $70.00 to $90.00. On average, they anticipate Myokardia's stock price to reach $80.00 in the next twelve months. This suggests a possible upside of 52.0% from the stock's current price. View Analyst Price Targets for Myokardia.

What is the consensus analysts' recommendation for Myokardia?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myokardia in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Myokardia.

What are Wall Street analysts saying about Myokardia stock?

Here are some recent quotes from research analysts about Myokardia stock:
  • 1. According to Zacks Investment Research, "MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California. " (8/13/2019)
  • 2. Cantor Fitzgerald analysts commented, ": 12-month price target of $90. MYOK reported earnings this evening and an increased cash balance of ~ $630M after raising capital in 1Q19. We think that the company is well-capitalized to take advantage of its research discovery platform. One key update today was that the MAVERICK study (non-obstructive) has completed enrollment. We expect that this study will be an important catalyst for the company in 4Q19; we still think that current share levels do not reflect credit for non-obstructive. We still see additional pipeline catalysts beyond mavacamten in obstructive in 2H 2019 that keep us very positive on shares at the current level." (5/9/2019)

Has Myokardia been receiving favorable news coverage?

Headlines about MYOK stock have trended negative on Tuesday, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Myokardia earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Myokardia.

Who are some of Myokardia's key competitors?

What other stocks do shareholders of Myokardia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myokardia investors own include Exelixis (EXEL), Micron Technology (MU), CVS Health (CVS), CA (CA), BlackRock (BLK), Kratos Defense & Security Solutions (KTOS), Johnson & Johnson (JNJ), Amgen (AMGN), NVIDIA (NVDA) and Raytheon (RTN).

Who are Myokardia's key executives?

Myokardia's management team includes the folowing people:
  • Mr. Tassos Anastasios Gianakakos, Pres, CEO & Director (Age 46)
  • Dr. Robert S. McDowell, Chief Scientific Officer (Age 61)
  • Dr. June Lee, Exec. VP & Chief Devel. Officer (Age 53)
  • Dr. Charles J. Homcy, Advisor (Age 71)
  • Dr. Eric J. Topol, Advisor (Age 65)

Who are Myokardia's major shareholders?

Myokardia's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.06%), BlackRock Inc. (7.82%), Price T Rowe Associates Inc. MD (7.63%), Farallon Capital Management LLC (4.34%), Perceptive Advisors LLC (2.39%) and Orbimed Advisors LLC (2.07%). Company insiders that own Myokardia stock include Anastasios Gianakakos, Jake Bauer, Joseph Lambing, June Lee, Kevin P Starr, Marc Semigran, Rock Ventures Ii LP Third, Sanofi and Taylor C Harris. View Institutional Ownership Trends for Myokardia.

Which major investors are selling Myokardia stock?

MYOK stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Bank of America Corp DE, Cormorant Asset Management LP, Victory Capital Management Inc., D. E. Shaw & Co. Inc., Bank of Montreal Can, Strs Ohio and Handelsbanken Fonder AB. Company insiders that have sold Myokardia company stock in the last year include Anastasios Gianakakos, Jake Bauer, June Lee, Sanofi and Taylor C Harris. View Insider Buying and Selling for Myokardia.

Which major investors are buying Myokardia stock?

MYOK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Primecap Management Co. CA, Vanguard Group Inc., Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Perceptive Advisors LLC, First Light Asset Management LLC and grace capital. Company insiders that have bought Myokardia stock in the last two years include Anastasios Gianakakos and Sanofi. View Insider Buying and Selling for Myokardia.

How do I buy shares of Myokardia?

Shares of MYOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Myokardia's stock price today?

One share of MYOK stock can currently be purchased for approximately $52.6450.

How big of a company is Myokardia?

Myokardia has a market capitalization of $2.43 billion and generates $33.56 million in revenue each year. The biotechnology company earns $-67,700,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Myokardia employs 165 workers across the globe.View Additional Information About Myokardia.

What is Myokardia's official website?

The official website for Myokardia is http://www.myokardia.com/.

How can I contact Myokardia?

Myokardia's mailing address is 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-741-0900 or via email at [email protected]


MarketBeat Community Rating for Myokardia (NASDAQ MYOK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  229 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about Myokardia and other stocks. Vote "Outperform" if you believe MYOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel